AZD8055: Practical mTOR Inhibitor Workflow

AZD8055, SKU A8214, is a selective ATP-competitive mTOR kinase inhibitor used to perturb both mTORC1 and mTORC2 signaling in biochemical, cellular, and selected animal experiments. No directly matched paper evidence is available in the supplied record, so the workflow below is based on the product dossier and standard experimental design practices rather than on a newly identified publication or trial dataset.

What This Product Solves

Many pathway studies need a tool that inhibits mTOR kinase activity rather than only one downstream complex. AZD8055 addresses this requirement as a dual mTORC1/mTORC2 inhibitor. The dossier reports an mTOR kinase IC50 of 0.8 nM and describes competitive binding at the ATP-binding cleft. This makes the compound suitable for experiments examining how mTOR kinase inhibition changes cell growth, proliferation, survival, motility, and metabolism.

For cancer research, the product dossier describes reduced proliferation in lung, cervical, and laryngeal cancer cell lines and acute myeloid leukemia models, as well as tumor-growth effects in several xenograft settings. In cell experiments, reduced Ki67 has been reported in breast cancer cell lines at nanomolar concentrations. These statements should be treated as dossier-level evidence and reproduced in the investigator’s own model; they do not replace model-specific dose-response and exposure studies.

AZD8055 is also useful for interrogating the PI3K/Akt/mTOR signaling network when paired with pathway-proximal and functional readouts. A selective mTOR signaling pathway inhibitor can help separate mTOR-dependent effects from broader kinase inhibition, but selectivity should still be confirmed under the exact assay conditions used. The product dossier reports approximately 1000-fold selectivity over related kinases, including PI3K isoforms and ATM/DNA-PK, with no significant activity across a panel of 260 kinases at 10 μM.

For product identity, chemical properties, and handling information, consult the AZD8055 product page from APExBIO. The handling-focused companion article, AZD8055: Practical mTOR Inhibitor Workflow, complements this article with additional emphasis on DMSO-based preparation. The parameter-focused companion article, AZD8055: Technical Parameters and Best Practices for mTOR Inhibition, is useful when planning assay controls and reproducibility checks.

Protocol Parameters

Protocol Parameters

The values below distinguish product specifications from investigator-defined workflow recommendations. Do not interpret the product’s biochemical potency as a guaranteed cellular working concentration.

• Assay: Recombinant mTOR kinase assay. Value: IC50 0.8 nM. Applicability: Biochemical potency benchmarking and assay qualification. Rationale: This establishes a reference point for ATP-competitive mTOR inhibition, while cellular potency will depend on ATP concentration, exposure, permeability, and model biology. This value is stated in the product dossier.
• Assay: Selectivity profiling. Value: Approximately 1000-fold selectivity; no significant activity reported against 260 kinases at 10 μM. Applicability: Interpretation of mTOR-focused biochemical results. Rationale: The comparison supports use as a selective mTOR kinase inhibitor, but it should not be used to assume complete absence of off-target effects in every cellular context. These values are stated in the product dossier.
• Assay: Stock-solution preparation. Value: Solubility of at least 23.3 mg/mL in DMSO; insoluble in water and ethanol. Applicability: Primary stock preparation and dilution planning. Rationale: DMSO should be the starting solvent, with precipitation checked after dilution into assay medium or buffer. These solubility values are product specifications.
• Assay: Storage and solution handling. Value: Solid stored at -20°C; solutions used promptly rather than stored long term. Applicability: Inventory control and preparation scheduling. Rationale: Limiting repeated handling and prolonged solution storage reduces uncertainty from concentration drift or compound instability. The temperature and solution-handling guidance come from the product dossier.
• Assay: Cellular proliferation and pathway response. Value: Nanomolar treatment range reported for reduced Ki67 in breast cancer cell lines. Applicability: Initial cancer-cell proliferation studies. Rationale: Use this only as a starting region for a model-specific concentration series, with vehicle matching and viability controls. The nanomolar observation is stated in the product dossier; the concentration series is a workflow recommendation.

Workflow Setup and QC Checklist

1. Define the biological question

Decide whether the primary endpoint is biochemical kinase inhibition, mTORC1 signaling, mTORC2 signaling, proliferation, or metabolism. For pathway studies, predefine at least one proximal signaling readout and one functional endpoint. Depending on the model, candidate readouts may include phosphorylation changes associated with mTORC1 or mTORC2, Ki67, cell counting, viability, or glucose and insulin measurements in an animal study. Do not infer pathway selectivity from a viability change alone.

2. Prepare and verify the compound

Bring the solid into the working area under the specified storage conditions and prepare a concentrated stock in DMSO. Mix until the solution is visually uniform, record the preparation date, and avoid unnecessary freeze-thaw cycles. Before adding the compound to aqueous medium or assay buffer, confirm that the final mixture remains clear or otherwise document any turbidity or precipitate. Prepare matched vehicle controls using the same DMSO exposure as treated samples.

3. Build the cellular experiment

Use a concentration series spanning below and above the expected response region rather than testing one concentration. Include untreated and vehicle controls, identical cell seeding conditions, and a time course appropriate to the endpoint. Measure both pathway response and cell-state consequences; for example, pair a signaling measurement with Ki67, cell number, or viability. Keep medium composition, serum status, plate position, and treatment timing consistent because these variables can alter mTOR pathway activity.

4. Control the biochemical assay

For an ATP-competitive inhibitor, maintain a defined ATP concentration and report the assay matrix, enzyme source, incubation sequence, and detection method. If comparing experiments, keep ATP and substrate conditions constant. Include a no-enzyme or assay-background control and a vehicle control. A potency value obtained under one ATP condition should not be transferred unchanged to a different biochemical format.

5. Review QC before interpretation

Inspect raw signal, replicate agreement, vehicle performance, and evidence of precipitation or edge effects. Confirm that the compound concentration calculation reflects the molecular weight of 465.54 and the actual stock volume. For animal work, perform formulation and tolerability checks before the efficacy experiment, and prespecify glucose and insulin sampling procedures if studying the dossier-described metabolic response after intraperitoneal administration.

Common Failure Modes and Fixes

• Visible precipitation after dilution: The compound is insoluble in water and ethanol. Recheck the DMSO stock, reduce the dilution step, add the stock gradually with mixing, and inspect the final assay mixture before interpreting a negative result.
• Apparent cytotoxicity in every treatment: Check final DMSO exposure, cell density, medium changes, and compound carryover. Compare pathway markers with viability so solvent stress is not mistaken for mTOR-specific biology.
• Weak or inconsistent pathway inhibition: Verify stock concentration, treatment timing, ATP conditions in biochemical assays, and the dynamic range of the detection method. Confirm that the chosen model expresses a measurable baseline mTOR response.
• High replicate variability: Standardize cell seeding, mixing order, incubation timing, and plate layout. Use freshly prepared working solutions and document the interval between dilution and treatment.
• Loss of reproducibility between runs: Review storage history and avoid long-term storage of solutions. Repeat the experiment with a fresh DMSO stock and include the same vehicle and reference controls.

Scope and Limitations

AZD8055 is appropriate for mechanistic preclinical work on mTOR biology, cancer-cell proliferation, and selected metabolic responses. The dossier also describes enhanced activity with HDAC inhibitors and MEK inhibitors, but combination experiments require independent matrix design, interaction analysis, and toxicity controls. A response to a combination should not automatically be attributed to pathway synergy.

The compound is a solid with formula C25H31N5O4 and molecular weight 465.54. Its poor aqueous solubility limits workflows that require direct water-based preparation. Although the dossier describes oral bioavailability and systemic biological activity in animal studies, route, dose, exposure, and tolerability must be established for each model rather than inferred from the product description.

Most importantly, the supplied record contains no directly matched paper evidence for a specific experimental question. The product dossier reports preclinical activity across multiple models and minimal clinical benefit in phase I trials; these points support a research-tool application but do not establish clinical utility. Results should therefore be presented as model-specific pharmacology, with formulation, exposure, selectivity, and assay limitations stated explicitly.

Conclusion

AZD8055 provides a practical way to inhibit mTOR kinase activity across both mTORC1 and mTORC2 signaling in controlled research workflows. Its strongest use case is mechanistic analysis supported by matched vehicle controls, pathway and functional readouts, and careful DMSO-based formulation. Use the reported 0.8 nM biochemical IC50 and nanomolar cellular observation as dossier reference points, not universal operating concentrations, and validate every model with its own dose-response, exposure, and QC data.